ilona75/iStock via Getty Images The U.S. Department of Agriculture has approved Merck ( NYSE: MRK ) Animal Health's vaccine NOBIVAC NXT Canine Flu H3N2, which uses RNA-particle technology.
The pharma said the RNA technology behind the shot provides a more precise immune response against a range of pathogens. The shot is indicated for dogs eight weeks and older. NOBIVAC NXT is expected to be available late this summer.
More on Merck Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck gets FDA approval for Capvaxive pneumonia vaccine (update) Merck's Keytruda gains approval for additional endometrial carcinoma indication Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Merck & Co.
, Inc. (MRK) Investor Event at ASCO 2024 (Transcript).
